• Recent trials highlight the potential of salt substitution and restriction in lowering blood pressure, particularly in elderly care facilities, showcasing significant cardiovascular benefits.
• Emerging drug therapies, including aldosterone synthase inhibitors like baxdrostat and lorundrostat, demonstrate efficacy in treatment-resistant hypertension by targeting aldosterone production.
• Bariatric surgery has shown sustained reductions in blood pressure over five years in obese patients with hypertension, suggesting a durable impact on cardiovascular health.
• SGLT2 inhibitors, initially for diabetes, are recognized for their beneficial effects on blood pressure regulation, offering a dual-action approach for patients with both conditions.